Science Current Events | Science News | Brightsurf.com
 

Drug combination may provide option to patients with NSCLC ineligible for bevacizumab

April 03, 2012
CHICAGO - A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

"The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab," said Gregory A. Otterson, M.D., professor of internal medicine, co-director of the thoracic oncology program and associate director of the hematology and medical oncology fellowship program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio.

Otterson and colleagues evaluated the drug combination in 63 patients with advanced NSCLC. Seventy-six percent of patients had squamous histology, making them ineligible for bevacizumab. Other contraindications for bevacizumab among this patient population included hemoptysis, thrombosis and therapeutic anticoagulation. Researchers assigned patients to 300 mg/m2/AUC6, which was later adjusted to 260 mg/m2/AUC6 due to excess neuropathy, every 21 days.

Researchers found an overall response rate of 41 percent among 53 patients available for evaluation. An additional 39 percent of patients had stable disease for at least six weeks. Disease progressed in 19 percent of patients.

"We have been surprised at the durability of response with some patients not requiring further treatment for at least six months," Otterson said.

More than 10 percent of patients had grade 3 to 4 toxicities, including hematologic toxicity, febrile neutropenia, infection, sensory neuropathy, dyspnea and dehydration; researchers reported four deaths as grade 5 toxicities. "This combination treatment should be an option, particularly for patients with squamous histology who have limited alternative options," Otterson said.

American Association for Cancer Research


Related Bevacizumab Current Events and Bevacizumab News Articles


Thin colorectal cancer patients have shorter survival than obese patients
Although being overweight with a high body-mass index (BMI) has long been associated with a higher risk for colorectal cancer, thinner patients might not fare as well after treatment for advanced cancer, according to a new study from Duke Medicine.

Mayo Clinic study suggests which glioblastoma patients may benefit from drug treatment
Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit.

Development of new blood vessels not essential to growth of lymph node metastases
While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed.

Study suggests new way of preventing diabetes-associated blindness
Reporting on their study with lab-grown human cells, researchers at The Johns Hopkins University and the University of Maryland say that blocking a second blood vessel growth protein, along with one that is already well-known, could offer a new way to treat and prevent a blinding eye disease caused by diabetes.

TGen-UCSF study in Neuro-Oncology provides comprehensive look at brain cancer treatments
Led by the Translational Genomics Research Institute (TGen) and UC San Francisco (UCSF), a comprehensive genetic review of treatment strategies for glioblastoma brain tumors was published today in the Oxford University Press journal Neuro-Oncology.

Allow NHS doctors to prescribe cheap, safe and effective sight loss drug, says The BMJ
NHS doctors should be allowed to prescribe a cheap, safe and effective drug for the degenerative eye disease, wet age related macular degeneration (AMD) - a leading cause of blindness among older patients, says an investigation by The BMJ today.

Tumor location in colorectal cancer may influence survival
The two halves of the human colon have different embryonic origins and gene expression patterns, and these differences may also play a role in cancer biology, according to a study published February 24 in the JNCI: Journal of the National Cancer Institute.

Breast Cancer Specialist Presents Positive Results for Triple-Negative Breast Cancer Presurgery Chemotherapy Benefits
A breast cancer specialist and clinical researcher at Women & Infants Hospital of Rhode Island presented research yesterday at the 2014 San Antonio Breast Cancer Symposium showing that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer.

Kidney cancer patients respond well to a combination of 2 existing anti-cancer drugs
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs.

Adding cediranib to chemo improves progression-free survival for meta or recurrent cervical cancer
For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid.
More Bevacizumab Current Events and Bevacizumab News Articles

AVASTIN (Bevacizumab): Treats Cancer, including Colorectal, Lung, Glioblastoma, Kidney, Cervical, and Ovarian Cancer

AVASTIN (Bevacizumab): Treats Cancer, including Colorectal, Lung, Glioblastoma, Kidney, Cervical, and Ovarian Cancer
by James Lee Anderson (Author)


“Although, your health condition may impact your everyday life, do not let it define who you are.” AVASTIN (Bevacizumab) injection is given with other medicines to treat patients with metastatic (a cancer that has spread) carcinoma of the colon or rectum. This medicine is also used to treat a certain type of metastatic lung cancer called nonsquamous, non-small cell lung cancer, and a certain type of brain tumor called glioblastoma. AVASTIN (Bevacizumab) is a substance that helps the body fight cancer. It prevents the growth of certain types of blood vessels to cancer cells. This helps to decrease the growth of cancer cells by starving the cells of nutrients that are needed to grow. AVASTIN (Bevacizumab) injection is also used in combination with other medicines (eg, interferon alfa)...

Bevacizumab: Webster's Timeline History, 2001 - 2007

Bevacizumab: Webster's Timeline History, 2001 - 2007
by Icon Group International (Author)


Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Bevacizumab," including when used in literature (e.g. all authors that might have Bevacizumab in their name). As such, this book represents the largest compilation of timeline events associated with Bevacizumab when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...

Eficacia comparada: XELOX vs XELOX+Bevacizumab en cancer colorrectal metastasico: Trabajo Diploma Oncologia Farmaceutica. Edicion 2010. Universidad de Valencia. (Spanish Edition)

Eficacia comparada: XELOX vs XELOX+Bevacizumab en cancer colorrectal metastasico: Trabajo Diploma Oncologia Farmaceutica. Edicion 2010. Universidad de Valencia. (Spanish Edition)
by Marta Mª Valera Rubio (Author)


Estudio comparativo de eficacia entre el esquema XELOX y el esquema XELOX+Bevacizumab en cáncer colorrectal metastásico en una población de un hospital de tercer nivel.

All About Bevacizumab

All About Bevacizumab
by Aneta Zygulska (Author), Krzysztof Krzemieniecki (Author)


Remission during sunitinib (a multikinase inhibitor and antiangiogenic drug) treatment correlates with appearance of macrocytosis. There are some suggestions that bevacizumab, an antiangiogenic drug, may result in macrocytosis as well. No available published data on the influence of bevacizumab on macrocytosis has been so far. This paper attempts to answer the question: does bevacizumab induce macrocytosis being a predictor of the response? Moreover, treatment of solid tumors and non-cancerous diseases is discussed in the second part of this paper.

Introducción a la genética humana, 3ª ed. (Spanish Edition)

Introducción a la genética humana, 3ª ed. (Spanish Edition)
by Editorial El Manual Moderno


Los autores de la primera y segunda edición de esta obra, fuimos los Drs. Salvador Armendares y un servidor. Ya han pasado 18 años desde que apareció la primera y 11 de la segunda, por lo que parecía necesario actualizarla una vez más, en vista de los avances considerables del conocimiento en esta área. Para ello y dado el fallecimiento de Salvador en enero de 2010, me pareció necesario invitar a colaborar a dos distinguidos colegas. La Dra. Patricia Grether González, ex alumna mía, conocedora de los aspectos clínicos de la genética y el Dr. Alejandro Zentella Dehesa, investigador básico en el campo de la biología molecular a quien conozco hace relativamente pocos años pero quien parece tener la capacidad de expresar temas complejos de una manera sencilla, característica...

Colorectal Cancer: Evidence-based Chemotherapy Strategies (Current Clinical Oncology)

Colorectal Cancer: Evidence-based Chemotherapy Strategies (Current Clinical Oncology)
by Leonard B. Saltz (Editor)


Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an array of supportive medications, have shown substantial progress and undergone a dramatic proliferation over the past decade. With the increased number of therapeutic options from which to choose, the clinician is better able to offer effective therapy to the patient with colorectal cancer. The clinician is challenged, however, to keep up with the rapidly changing landscape and the rapidly...

  Cotargeting VEGF and Neuropilins with Bevacizumab and Secreted Wnt Inhibitors in Prostate Cancer
by Xiaolin Zi (Author)




Diabetes, obesidad y síndrome metabólico. Un abordaje multidisciplinario (Spanish Edition)

Diabetes, obesidad y síndrome metabólico. Un abordaje multidisciplinario (Spanish Edition)
by Editorial El Manual Moderno


La presente obra es un compendio multidisciplinario que busca abordar este trinomio que peligrosamente se perfila como la pandemia del siglo XXI. El objetivo del proyecto desde que se gestó en 2011, ha sido plasmar las experiencias, tanto vivenciales como observadas bajo el ojo científico de los autores, tratando de dar al lector un panorama más o menos completo de las diversas perspectivas sobre las que se puede hablar de estas patologías.

Si bien es cierto todavía quedan muchos debates sobre la mesa al respecto de terapias, pruebas diagnósticas adecuadas, cuadros sintomáticos que permitan al médico definir de manera adecuada los síndromes, las enfermedades, etc., se buscó en su conjunto proporcionarle a la obra el mejor sentido homólogo evitando datos y evidencias...

Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer: Expert Consult (Early Diagnosis in Cancer)

Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer: Expert Consult (Early Diagnosis in Cancer)
by Saunders


Each volume in the Early Detection and Treatment of Cancer Series is packed with practical, authoritative information designed to cover the full range of diagnostic procedures, including pathologic, radiologic, bronchoscopic, and surgical aspects. You’ll be able to determine the safest, shortest, least invasive way to reach an accurate diagnosis; stage the disease; and choose the best initial treatment for early stages. Based on current evidence in the literature, authors provide clinical, hands-on tools to help you make informed decisions on precisely what tests and imaging studies are needed to diagnose and stage each type of cancer. Practical, authoritative, and highly-illustrated, this volume in the brand new Early Detection and Treatment of Cancer series covers current protocols...

Physicians' Cancer Chemotherapy Drug Manual 2015

Physicians' Cancer Chemotherapy Drug Manual 2015
by Edward Chu (Author), Vincent T. DeVita Jr. (Author)


Completely revised and updated for 2015, the Physicians’ Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens―both on- and off-label―for the treatment of all the major cancers. SPECIAL FEATURES: • Revised to reflect rapid advances in the field, incorporating treatment strategies and new drugs like afatinib, ceritinib, ibrutinib, idelalisib, obinutuzumab, and ramucirumab. • A specific chapter focused on profiling antiemetic drugs and antiemetic treatment regimens. • Diagrams of drug structures and pathways for many of...

© 2015 BrightSurf.com